CD4 News and Research

RSS

TSRI scientists identify small subset of immune cells that play major role in development of Crohn's disease

Two-thirds to three-quarters of the estimated 700,000 Americans living with Crohn's disease, an autoimmune condition that can disrupt the entire gastrointestinal tract, will require surgery at some point during their life.

9 Jan 2014

The fight against HIV/AIDS: an interview with Dr. Mit Philips, HIV/AIDS Policy Analyst, Médecins Sans Frontières (MSF)

People mainly speak about the progress in HIV/AIDS. We at MSF know and are very conscious of the fact that there has been enormous progress, but the progress is very uneven.

6 Jan 2014

Autoimmune clue to narcolepsy

Researchers have identified immune cells in patients with narcolepsy that react against hypocretin, the lack of which causes the disorder.

20 Dec 2013

Detectable blood viral load increases prevalence of heart disease

HIV causes structural heart disease according to research presented at EuroEcho-Imaging 2013 by Dr Nieves Montoro from Madrid, Spain. The findings support the introduction of cardiovascular screening in all HIV patients, particularly those with a positive blood viral load.

11 Dec 2013

Johns Hopkins researchers discover some cases of scleroderma likely to be initiated by cancer

The Scleroderma Research Foundation today reported that researchers at The Johns Hopkins University have discovered that some cases of scleroderma are likely to have been initiated by cancer.

6 Dec 2013

BAL findings boost non-smoking COPD distinction

Research shows that smoking status, and not airway obstruction, determines the distribution of T cell subsets in bronchoalveolar lavage in patients with chronic obstructive pulmonary disease.

2 Dec 2013

InnaVirVax starts VAC-3S Phase 2 clinical trial for treatment of HIV-1 infection

InnaVirVax SA today announced the initiation of a Phase 2 clinical trial assessing the therapeutic properties of the VAC-3S vaccine when combined with standard antiretroviral therapy in the course of HIV-1 infection.

1 Dec 2013

Ascend, 3M partner to develop and evaluate novel immunotherapy treatments for cancer

Ascend Biopharmaceuticals today announces that is has entered into an agreement with 3M Drug Delivery Systems to evaluate 3M’s Toll-Like Receptor 7/8 (TLR7/8) agonist 3M-051 in combination with Ascend’s proprietary cancer vaccine technology. The collaboration will support the creation and preclinical assessment of novel immunotherapy treatments to be potentially used for a number of different solid tumor types.

29 Nov 2013

Government of Canada awards $8.76M in funding to develop cure for HIV

In the push for a cure for HIV, the Government of Canada has announced $8.76 million in funding to Université de Montréal and Institut de recherches cliniques de Montréal Professor éric A. Cohen, who will lead an unrivaled group of Canadian investigators and international collaborators with a strong track record of interactive research.

29 Nov 2013

DNA vaccine demonstrates potential to prevent and treat deadly MERS coronavirus

Inovio Pharmaceuticals, Inc. announced today that preclinical testing of a DNA synthetic vaccine for the virulent Middle East Respiratory Syndrome coronavirus (MERS) induced robust and durable immune responses, demonstrating the potential for a SynCon DNA vaccine to prevent and treat this deadly virus.

20 Nov 2013

Discovery could rev up body's immune response to infection, autoimmune diseases

UT Southwestern Medical Center researchers report that disrupting the light-dark cycle of mice increased their susceptibility to inflammatory disease, indicating that the production of a key immune cell is controlled by the body's circadian clock.

8 Nov 2013

Researchers, clinicians discuss recent findings that could bring hope for people with HIV

Since the onset of the AIDS pandemic more than three decades ago, researchers from the lab and physicians in the clinic have been working toward one shared goal: an AIDS-free world. This week, a conference hosted by the journals Cell and The Lancet brought leading researchers and clinicians together to discuss recent findings that could bring hope to the estimated 35 million people world-wide who live with HIV.

7 Nov 2013

VG Life Sciences' peptide awarded US patent for HIV treatment

The United States Patent and Trademark Office has issued on October 15, 2013 Patent No.: US 8,557,764 covering the VG Life Sciences' peptide VG1177 for treating HIV infection.

31 Oct 2013

Immune Design closes Series C financing totalling up to $49M

Immune Design, a biotechnology company focused on the development of novel immune-based therapies for cancer and other chronic conditions, today announced it has closed a Series C financing totalling up to $49 million.

30 Oct 2013

HIV-positive patients with high CD4 cell counts are not at increased risk for heart attacks

Patients who are HIV-positive and have high CD4 cell counts - or have a high number of white blood cells that fight infections - aren't at an increased risk for heart attacks compared to patients who are HIV-negative, according to a Kaiser Permanente study that appears in the current online issue of the Journal of Acquired Immune Deficiency Syndromes.

25 Oct 2013

Scientists highlight novel way to develop universal influenza vaccine that can protect against multiple flu strains

A study led by St. Jude Children's Research Hospital scientists highlights a new approach for developing a universal influenza vaccine that could protect against multiple flu strains, including deadly pandemic strains. The research appears today in the advance online edition of the scientific journal Nature Immunology.

22 Oct 2013

European Commission approves updated label of Prevenar 13 for high risk pneumococcal disease

Pfizer Inc. (NYSE:PFE) announced today that the European Commission approved updates to the Summary of Product Characteristics (SmPC) for the company's pneumococcal conjugate vaccine Prevenar 13* (pneumococcal polysaccharide conjugate vaccine [13-valent, adsorbed]), regarding its use in certain populations at high risk of pneumococcal disease.

18 Oct 2013

UCLA study shows how cocaine makes immune cells susceptible to HIV

In many ways, the spread of HIV has been fueled by substance abuse. Shared needles and drug users' high-risk sexual behaviors are just some of the ways that narcotics such as cocaine have played a key role in the AIDS epidemic in much of the world.

3 Oct 2013

Mutant protein blocks HIV infection and transmission, scientists find

A mutant of an immune cell protein called ADAP (adhesion and degranulation-promoting adaptor protein) is able to block infection by HIV-1 (human immunodeficiency virus 1), new University of Cambridge research reveals. The researchers, who were funded by the Wellcome Trust, believe that their discovery will lead to new ways of combatting HIV.

2 Oct 2013

Use of cocaine may increase one's vulnerability to HIV infection

Cocaine use may increase one's vulnerability to HIV infection, according to a new research report published in the Journal of Leukocyte Biology. In the report, scientists show that cocaine alters immune cells, called "quiescent CD4 T cells," to render them more susceptible to the virus, and at the same time, to allow for increased proliferation of the virus.

1 Oct 2013